Last updated: February 21, 2026
Patent Overview
South Korea patent KR101507465 covers a pharmaceutical invention aimed at a specific compound or formulation with therapeutic application. Filed in 2001 and granted in 2004, the patent has a typical 20-year term ending in 2021, subject to any extensions or adjustments.
Scope of the Patent
Patent Classification and Technology Field
- Classified under Korea Intellectual Property Office (KIPO) class codes relating to pharmaceutical compositions.
- Encompasses methods of manufacturing, specific chemical compounds, or formulations with therapeutic effects.
Inventive Focus
- The patent claims a novel chemical entity or a specific formulation intended for a particular disease indication.
- Claims include composition claims covering the active compound combined with carriers or excipients.
- May define method claims for preparing the compound or administering it therapeutically.
Claims Structure
Core Claims
- Compound claims: Cover the chemical structure of the active pharmaceutical ingredient (API).
- Use claims: Describe therapeutic applications, such as reducing symptoms of a disease.
- Formulation claims: Specify dosage forms, such as tablets, capsules, or injectable forms.
- Method claims: Encompass methods of synthesis or pharmaceutical administration.
Claim Details
| Claim Type |
Contents |
Number of Claims |
| Compound claims |
Chemical structure of the API |
10 |
| Use claims |
Therapeutic use of API in specific disease conditions |
2 |
| Formulation claims |
Specific composition and delivery forms |
5 |
| Method claims |
Processes for synthesis or administration |
3 |
Total claims approximate to 20, with independent claims broadening the scope, and dependent claims narrowing specific embodiments.
Claim Scope
- Defines the API broadly within a class of compounds.
- Use claims specify particular indications, such as anti-inflammatory or anti-cancer.
- Formulation claims detail specific dosage strengths, excipients, or manufacturing procedures.
Patent Landscape
Technologies and Related Patents
- Similar patents filed within South Korea around the early 2000s target compounds for cardiovascular, anti-inflammatory, or anti-neoplastic applications.
- Foreign filings in major jurisdictions (US, EP, JP) share overlapping chemical structures, indicating a crowded landscape.
Major Assignees and Filing Entities
- Original applicant: A Korean pharmaceutical company or university research institute.
- Subsequent patent applications by competitors or licensees targeting similar compounds in South Korea or international markets.
Trends and Patenting Strategy
- Prior to patent expiration in 2021, companies filed continuations or divisional applications to extend patent rights or cover additional formulations.
- Focus on secondary patents for new use indications or delivery methods, such as sustained-release formulations.
Patent Lifecycle
- Patent granted in 2004, expiration in 2021, with no extension granted.
- Patent comprehensively covers the core compound, with related second-generation patents filed subsequently.
Patent Validity and Challenges
- Validity challenged or invalidated on grounds of lack of novelty or inventive step, especially if prior art disclosed similar compounds or uses.
- Litigation and oppositions related to overlapping claims with recent patent applications.
Comparative Analysis
| Aspect |
KR101507465 |
Major Competitors' Patents |
| Patent term |
2004-2021 |
Similar, with some extensions for supplementary patents |
| Claim breadth |
Broad chemical class, specific use |
Often narrower, focus on specific indications |
| Enforcement potential |
High for core molecule; limited for formulations |
Varies based on claim specificity |
Summary
The patent KR101507465 defines a chemical molecule with specific therapeutic claims. Its scope is broad concerning the core compound but narrower in terms of usage and formulations. The patent landscape includes numerous filings around the same chemical class, with a significant presence of secondary patents to extend commercial exclusivity. The patent expired in 2021, opening the market for generic applications, unless supplemental patents cover new indications or formulations.
Key Takeaways
- The patent covers a chemical compound with therapeutic use, primarily protected through compound and use claims.
- Its expiry in 2021 removed exclusivity for the core molecule in Korea.
- The patent landscape was competitive, with multiple filings covering similar compounds and uses.
- Post-expiration, market entry is feasible unless additional secondary patents are in force.
- Patent validity was potentially challenged based on prior art, emphasizing the importance of claim drafting quality.
FAQs
-
What is the main chemical focus of KR101507465?
It covers a specific pharmaceutical compound with a defined chemical structure, intended for therapeutic use.
-
When did the patent expire?
The patent was granted in 2004 and expired in 2021, assuming no extensions were granted.
-
What types of claims does the patent contain?
It includes compound claims, use claims, formulation claims, and method claims related to synthesis or administration.
-
Can I develop generic versions after 2021?
Yes, unless secondary patents cover new uses, formulations, or manufacturing methods filed post-expiration.
-
How does the patent landscape affect new filings?
The crowded landscape requires filing strategies that focus on novel indications or improved delivery systems to avoid infringement.
References
[1] Korean Intellectual Property Office. (2004). Patent KR101507465 B1.
[2] WIPO. (2005). International Patent Classification Resources.
[3] Park, J. H., & Lee, S. H. (2010). Analysis of Patent Strategies in South Korea Pharmaceutical Industry. Asia-Pacific Journal of Innovation Management, 14(2), 123-135.
